Role of positron emission tomography for the monitoring of response to therapy in breast cancer

Oncologist

Volumn 20, Issue 2, 2015, Pages 94-104

  Humbert, Olivier ^a,b,c   Cochet, Alexandre ^a,c   Coudert, Bruno ^a   Berriolo Riedinger, Alina ^a   Kanoun, Salim ^a   Brunotte, François ^a,b,c   Fumoleau, Pierre ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HÔPITAL DU BOCAGE   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

18F Fluorodeoxyglucose; Breast; Cancer; Monitoring; Positron emission tomography; Response

Indexed keywords

BEVACIZUMAB; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GAMMA UROGASTRONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VASCULOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CELL HETEROGENEITY; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TUMOR LEVEL; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME; BREAST NEOPLASMS; FEMALE; METABOLISM; PATHOLOGY; PROGNOSIS; RADIOGRAPHY;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84922695226     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0342     Document Type: Article

References (120)

1. Groheux D, Espi é M, Giacchetti S et al. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 2013;266:388-405.
2. Wahl RL, Zasadny K, Helvie M et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993;11:2101-2111.
3. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15: 2483-2493.
4. Gralow JR, Burstein HJ, Wood W et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814-819.
5. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
6. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804.
7. Schelling M, Avril N, Nährig J et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-1695.
8. Rousseau C, Devillers A, Sagan C et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucosepositron emissiontomography. J Clin Oncol 2006;24:5366-5372.
9. Berriolo-Riedinger A, Touzery C, Riedinger JM et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34: 1915-1924.
10. McDermott GM, Welch A, Staff RT et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007;102:75-84.
11. Kumar A, Kumar R, Seenu V et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19: 1347-1357.
12. Schwarz-Dose J, Untch M, Tiling R et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 2009;27:535-541.
13. Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDGPET after the first course. Breast Cancer Res Treat 2012;131:517-525.
14. Duch J, Fuster D, Muñoz M et al. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer. Q J Nucl MedMol Imaging 2012;56:291-298.
15. Duch J, Fuster D, Muñoz M et al. 18F-FDG PET/ CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl MedMol Imaging 2009;36:1551-1557.
16. Dunnwald LK, Doot RK, Specht JM et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: Value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011;17: 2400-2409.
17. Boellaard R. Need for standardization of 18FFDG PET/CT for treatment response assessments. J Nucl Med 2011;52(suppl 2):93S-100S.
18. Cheng X, Li Y, Liu B et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: A meta-analysis. Acta Radiol 2012;53:615-627.
19. Wang Y, Zhang C, Liu J et al. Is 18F-FDG PET accurateto predict neoadjuvant therapyresponse in breast cancer? A meta-analysis. Breast Cancer Res Treat 2012;131:357-369.
20. Mghanga FP, Lan X, Bakari KH et al. Fluorine-18 fluorodeoxyglucose positron emission tomographycomputed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-analysis. Clin Breast Cancer 2013;13:271-279.
21. Ohara M, Shigematsu H, Tsutani Y et al. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: Usefulness for malignant grade of triple-negative breast cancer. Breast 2013; 22:958-963.
22. Ahn SG, Lee M, Jeon TJ et al. [18F]-fluorodeoxyglucose positron emission tomography can contribute to discriminate patients with poor prognosis in hormone receptor-positive breast cancer. PLoS One 2014;9:e105905.
23. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
24. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
25. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
26. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-5685.
27. Bhargava R, Striebel J, Beriwal S et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009;2:444-455.
28. de Ronde JJ, Hannemann J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119:119-126.
29. Bhargava R, Beriwal S, Dabbs DJ et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer 2010;116:1431-1439.
30. Darb-Esfahani S, Loibl S, Muller BM et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: Role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009;11:R69.
31. García García-Esquinas M, García-Sáenz JA, Arrazola García J et al. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: Association of loco‑regional SUVmax with classical prognostic factors. Q J Nucl Med Mol Imaging 2014;58:66-73.
32. Humbert O, Berriolo-Riedinger A, Riedinger JM et al. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: Influence of tumor subtypes. Ann Oncol 2012;23:2572-2577.
33. Keam B, Im SA, Koh Y et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011;11:452.
34. Specht JM, Kurland BF, Montgomery SK et al. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010;16:2803-2810.
35. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.NEngl JMed 2005;353: 1659-1672.
36. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375: 377-384.
37. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001;344:783-792.
38. Groheux D, Giacchetti S, Hatt M et al. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer 2013;109: 1157-1164.
39. Humbert O, Cochet A, Riedinger JM et al. HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxanebased neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2014;41:1525-1533.
40. Koolen BB, Pengel KE, Wesseling J et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast 2013;22:691-697.
41. Koolen BB, Pengel KE, Wesseling J et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2014;41:32-40.
42. Gebhart G, Gámez C, Holmes E et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. J Nucl Med 2013;54:1862-1868.
43. Coudert B, Piergat JY, Mouret-Reynier MA et al. Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): An open-label, randomized phase 2 trial. Lancet Oncol 2014;15:1493-1502.
44. Boyle P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann Oncol 2012;23(suppl 6):vi7-vi12.
45. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
46. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
47. Basu S, Chen W, Tchou J et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: A potentially useful method for disease characterization. Cancer 2008;112: 995-1000.
48. Groheux D, Hindié E, Giacchetti S et al. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer 2014;50:1864-1871.
49. Groheux D, Hindié E, Giacchetti S et al. Triplenegative breast cancer: Early assessment with 18FFDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 2012;53:249-254.
50. Schneider-Kolsky ME, Hart S, Fox J et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010;12:R37.
51. Doot RK, Dunnwald LK, Schubert EK et al. Dynamic and static approaches to quantifying 18FFDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 2007;48:920-925.
52. Groheux D, Hatt M, Hindié E et al. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: Early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer 2013;119:1960-1968.
53. Humbert O, Berriolo-Riedinger A, Cochet A et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging 2014;41: 416-427.
54. Hatt M, Groheux D, Martineau A et al. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J NuclMed 2013;54:341-349.
55. Bruzzi P, Del Mastro L, Sormani MP et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005;23:5117-5125.
56. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
57. Eisenhauer EA, Therasse P, Bogaerts J et al.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
58. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s.
59. Harvey HA, Cream L. Biology of bone metastases: Causes and consequences. Clin Breast Cancer 2007;7(suppl 1):S7-S13.
60. Hamaoka T, Madewell JE, Podoloff DA et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-2953.
61. Hamaoka T, Costelloe CM, Madewell JE et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010;102:651-657.
62. Hayashi N, Costelloe CM, Hamaoka T et al. A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer 2013;13:24-30.
63. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009;50(suppl 1):55S-63S.
64. Du Y, Cullum I, Illidge TM et al. Fusion of metabolic functionandmorphology: Sequential [18F] fluorodeoxyglucose positron-emission tomography/ computedtomography studiesyieldnewinsights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25:3440-3447.
65. Schneider JA, Divgi CR, Scott AM et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994;35: 1748-1752.
66. Stafford SE, Gralow JR, Schubert EK et al. Use of serial FDG PET to measure the response of bonedominant breast cancer to therapy. Acad Radiol 2002;9:913-921.
67. Schwarz-Dose J, Bader M, Jenicke L et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-1150.
68. Couturier O, Jerusalem G, N’Guyen JM et al. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006;12:6437-6443.
69. Specht JM, Tam SL, Kurland BF et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007;105:87-94.
70. Cachin F, Prince HM, Hogg A et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006;24:3026-3031.
71. Tateishi U, Gamez C, Dawood S et al. Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/ CT. Radiology 2008;247:189-196.
72. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20:1771-1785.
73. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
74. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-3403.
75. Mortimer JE, Dehdashti F, Siegel BA et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19: 2797-2803.
76. Dehdashti F, Flanagan FL, Mortimer JE et al. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-56.
77. Kurland BF, Gadi VK, Specht JM et al. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res 2012;2:34.
78. Dehdashti F, Mortimer JE, Trinkaus K et al. PETbased estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2009;113:509-517.
79. Mortazavi-Jehanno N, Giraudet AL, Champion L et al. Assessment of response to endocrine therapy usingFDGPET/CT inmetastaticbreast cancer:Apilot study. Eur J Nucl Med Mol Imaging 2012;39: 450-460.
80. Carlson RW, Allred DC, Anderson BO et al. Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:821-829.
81. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-1782.
82. Wahl RL, Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(suppl 1):122S-150S.
83. Huyge V, Garcia C, Alexiou J et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol) 2010;22:818-827.
84. Heim S, Teixeira MR, Dietrich CU et al. Cytogenetic polyclonality in tumors of the breast. Cancer Genet Cytogenet 1997;95:16-19.
85. Teixeira MR, Pandis N, Bardi G et al. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 1996;56: 855-859.
86. Kenny LM, Vigushin DM, Al-Nahhas A et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res 2005;65:10104-10112.
87. Soloviev D, Lewis D, Honess D et al. [(18)F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 2012;48:416-424.
88. Kenny LM, Al-Nahhas A, Aboagye EO. Novel PET biomarkers for breast cancer imaging. NuclMed Commun 2011;32:333-335.
89. van Waarde A, Cobben DC, Suurmeijer AJ et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
90. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr PharmDes 2008;14:3326-3339.
91. Yue J, Chen L, Cabrera AR et al. Measuringtumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: A pilot clinical study. J NuclMed 2010;51:528-534.
92. Pio BS, Park CK, Pietras R et al. Usefulness of 39-[F-18]fluoro-39-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8: 36-42.
93. Contractor KB, Kenny LM, Stebbing J et al. [18F]-39-Deoxy-39-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 2011;17:7664-7672.
94. Contractor K, Aboagye EO, Jacob J et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3’-deoxy-3’-fluorothymidine PET: A pilot study. Biomarkers Med 2012;6:231-233.
95. Woolf DK, Beresford M, Li SP et al. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer 2014;110: 2847-2854.
96. Kostakoglu L. Phase II study of 39-deoxy-39-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; May30 to June 3, 2014; Chicago, IL.
97. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
98. Mankoff DA, Dunnwald LK, Gralow JR et al. Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 2002;43:500-509.
99. Mankoff DA, Dunnwald LK, Gralow JR et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-1814.
100. Dunnwald LK, Gralow JR, Ellis GK et al.Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008; 26:4449-4457.
101. Eby PR, Partridge SC, White SW et al.Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246-1254.
102. Tseng J, Dunnwald LK, Schubert EK et al. 18FFDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvantchemotherapy. J NuclMed 2004;45:1829-1837.
103. Mullani NA, Herbst RS, O’Neil RG et al.Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15Olabeled water-measured blood flow. J Nucl Med 2008;49:517-523.
104. Cochet A, Pigeonnat S, Khoury B et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: Comparison with angiogenesis markers and prognostic factors. J Nucl Med 2012;53:512-520.
105. Beer AJ, Niemeyer M, Carlsen J et al. Patterns of alphavbeta3expression in primary andmetastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49:255-259.
106. Beer AJ, Haubner R, Sarbia M et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12:3942-3949.
107. Beer AJ, Haubner R, Wolf I et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006;47:763-769.
108. Gaykema SB, Brouwers AH, Lub-de Hooge MNet al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013;54:1014-1018.
109. O’Flynn EA, DeSouza NM. Functional magnetic resonance: Biomarkers of response in breast cancer. Breast Cancer Res 2011;13:204.
110. Chung GG, Zerkowski MP, Ghosh S et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007;87:662-669.
111. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-592.
112. van Kruchten M, de Vries EG, Brown M et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 2013;14:e465-e475.
113. Linden HM, Stekhova SA, Link JM et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24: 2793-2799.
114. Dijkers EC, Kosterink JG, Rademaker AP et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50:974-981.
115. Dijkers EC, Oude Munnink TH, Kosterink JG et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586-592.
116. Gaykema SB, Brouwers AH, Hovenga S et al. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol 2012;30: e74-e75.
117. Gaykema SB, Schröder CP, Vitfell-Rasmussen J et al. 89Zr-trastuzumab and 89Zrbevacizumab PET to evaluate the effect of the HSP90 inhibitorNVP-AUY922 inmetastatic breast cancer patients. Clin Cancer Res 2014;20: 3945-3954.
118. Gebhart G. PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer. Oral abstract presented at: Annual Meeting of the American Society of Clinical Oncology; May 30 to June 3, 2014; Chicago, IL.
119. Dehdashti F, Laforest R, Gao F et al. Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16a, 17a-[(R)-(19-a-furylmethylidene)dioxy]-19-norpregn-4-ene-3, 20-dione. J NuclMed 2012;53: 363-370.
120. Linden HM, Kurland BF, Peterson LM et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011;17:4799-4805.